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A report on the first EMBO conference entitled “Next
Gen Immunology—From Host Genome to the
Microbiome: Immunity in the Genomic Era”, held at
the Weizmann Institute of Science, Israel, 14–16
February, 2016.physiological and pathological states.The first Next Gen Immunology EMBO conference, held
at the Weizmann Institute of Science in mid-February,
touched upon a broad set of topics from host genetics to
transcriptomics and microbiome analysis. It specifically
demonstrated the intimate cross-talk between the micro-
biome and the immune system and called for a similarly
close interdisciplinary collaboration between microbiolo-
gists and immunologists. Recent years have exhibited an
increasing number of works on the modulation of the
microbiome by the immune system [1–3] and the effect
of the microbiome on the healthy development of im-
munity [4, 5] as well as on autoimmune disorders [6–8].
Groundbreaking research on these topics was presented,
along with new research methods, resulting in a broad
spectrum of exciting works. Finally, novel therapeutic di-
rections were demonstrated that probe and modulate
host–microbiome interactions, and show great promise
for future research. Here, we highlight several research
topics that are of interest to the scientific and biomedical
communities.
Microbial signatures of disease
With major advances in sequencing came the current
advent of microbiome research. In the past two decades
the composition and function of the microbiome have
been shown to associate with obesity, inflammatory* Correspondence: eran.segal@weizmann.ac.il
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tional choices, drug treatment, and many other physio-
logical and pathological states. The conference discussed
two major drivers in the field of microbiome research:
the better and deeper understanding of the microbial
signatures themselves and applications of this improved
understanding to study finer and more complex host
Quite a few novel approaches for microbiome analysis
were presented in the conference. A pioneer in the field
of microbiome research, Rob Knight (University of Cali-
fornia, San Diego, USA) highlighted the importance of
following the microbiome of individuals over time. Using
a three-dimensional principal coordinate analysis of the
compositions of microbiomes, Knight presented a visual
method for microbiome diagnostics. He showed that
even though the composition of the microbiome may
fluctuate over time, it remains unique for different
people. Julie Segre (National Institutes of Health, USA)
presented a computational pipeline for the examination
of the skin microbiome, allowing the exploration of
different strains and of the pangenome versus the
core genome of different species. Sharon Greenblum
(University of Washington, USA) presented a different
pipeline, for the detection of strain-level gene copy num-
ber variations.
Many speakers discussed new insights obtained using
diverse analysis methods. Knight showed that his
visualization method can be used to follow the devel-
opment of the neonatal microbiome and in the future
identify risk for allergies and asthma in aberrantly de-
veloping microbiomes. Ramnik Xavier (Broad Institute,
USA) examined infants genetically predisposed to type
I diabetes and showed that the disease is anticipated by
a reduction of diversity in gut microbial species. He
further described a difference in bacteria metabolizing
human milk oligosaccharide (HMO) in different coun-
tries, with a possible contribution to host immunity. A
working hypothesis presented was that bacterial
colonization, followed by HMO metabolism by immune-s distributed under the terms of the Creative Commons Attribution 4.0
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to autoimmunity. Moran Yassour (Broad Institute, USA)
presented results from a longitudinal cohort of 40 children
who consumed or abstained from antibiotic consumption,
and showed a prolonged reduction of microbial diversity
in children that are prescribed repeated courses of antibi-
otics, also resulting in less stable communities, reduced
intraspecies diversity, and transient increase in antibiotic
resistance genes.
Segre showed surprising figures of viral and fungal
content in the skin microbiome and a shift in its com-
position going through puberty. She presented her work
on atopic dermatitis, showing that two bacterial species,
Staphylococcus aureus and Staphylococcus epidermidis,
rise in abundance during flares of the disease. Eran Elinav
(Weizmann Institute of Science, Israel) presented a collab-
orative project with our lab that addressed the issue of re-
current obesity, which may be linked to the microbiome,
thereby impeding dieting and weight management.
The microbiome as an immunomodulator
Another central theme of the conference was the recog-
nition of the important role of the microbiome in host
immune maturation and in immunological health and
disease. The microbiome was shown to affect many im-
mune pathways, including innate immunity, inflamma-
somes, and regulatory T cells.
Andrew MacPherson (University of Bern, Switzerland)
showed that the microbiota in pregnancy shapes neonate
immunity, and specifically that innate immunity can be
transferred between mother and offspring in the absence
of the immunomodulating agent. Macpherson colonized
pregnant germ-free mice with an Escherichia coli strain
which infects the host transiently, thus decoupling the
effect of gestational and postnatal maternal microbiome.
Finally, he showed that such colonization initiates the
transfer of microbial molecules to the offspring, causing
them to develop innate immunity to the same E. coli.
The effect of the maternal microbiome on offspring
health was underlined by Dan Littman (Skirball Institute
of Biomolecular Medicine, New York University, USA)
who showed that simulating a viral infection with poly
I:C at gestational day 12.5 leads to autism spectrum dis-
order (ASD)-like symptoms in mice offspring. This
process is blocked with anti-interleukin (IL)-6 or anti-
IL-17 antibodies which affect maternal T-cell differenti-
ation. Since T-cell differentiation is also modulated by
gut microbiota, this work shows a possible role for the
maternal microbiome in offspring ASD.
Fiona Powrie (Oxford University, UK) showed that a
polysaccharide derived from Helicobacter hepaticus
regulates IL-10 and Treg response in the gut but not
IL-6 and tumor necrosis factor-alpha, modulating the
immune response and allowing the bacteria to prosperin the resulting niche. Such discoveries hold promise
for future therapies modulating host immunity using
microbiome modulation and microbiome-derived
metabolites.
Technological advances
Many new methodological and technological advances
were presented in the meeting. Feng Zhang (Massachusetts
Institute of Technology, USA) discussed the CRISPR tech-
nology, and presented his efforts to improve its specificity
by introducing mutations that reduce the ability of Cas9 to
stabilize incorrect guide matches. He also presented the
process of identifying “new” CRISPR systems, and specific-
ally the FnCpf1 system, which has a simple RNA guide,
cuts with sticky end, and is independent of the RNA poly-
merase III enzyme of the host—allowing for a simpler sys-
tem which is more efficient in many cases. The potential of
the CRISPR technology is just starting to unfold, with
works such as that of Jonathan Schmid-Burgk (University
of Bonn, Germany) who used it to knockout multiple
genes, identifying key genes to NLRP3 inflammasome acti-
vation, such as NEK7. A complementary approach was
taken by Nobel laureate Bruce Beutler (University of Texas
Southwestern, USA), who found the dominant role of
NEK7 in the activation of the NLRP3 inflammasome,
enforcing mutual exclusivity of cell division and the
inflammasome response, by assaying the phenotypic effect
in a forward genetic analysis of N-ethyl-N-nitrosourea-
induced mutagenesis in mice.
Timm Schroeder (ETH Zurich, Switzerland) made a
claim for continuously following and quantifying the fate
of stem cells at the single-cell level. He presented his ap-
proach, by combining time-lapse microscopy, cellular
markers, and computational analysis. This allows him to
identify decision-making points and combine them with
single-cell approaches to descend into molecular
mechanisms. Ilana Kolodkin-Gal (Weizmann Institute
of Science, Israel) utilized X-ray for the study of biofilms,
arguing for a dominant role for minerals in their forma-
tion and function. She showed that three-dimensional
biofilm formation is associated with and dependent on
crystalline calcium carbonate deposition, which allows
for control of diffusion, potentiating antibiotic resist-
ance within the biofilm.
Michael Fischbach (University of California, San
Francisco, USA) presented his methodology for novel
biocompound discovery, which involves prediction of
molecular products of genetic sequences, instead of
the common course of first finding a molecule of inter-
est and then looking for the biosynthesizing enzymes.
This is a much needed approach, as even the best-
studied organisms have many genes whose products
are unknown. The same idea applies to gene clusters in
the human microbiome, as most are not characterized,
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Project samples. A striking example is indoxyl sulfate,
which is created in a manner that is dependent upon
microbial metabolism of diet-derived molecules and is
toxic to kidney patients.
Transcription regulation in host immune response
One way by which exogenic compounds exert their effect
on the host is by altering transcription, and the topic of
transcription regulation was widely discussed during the
meeting. Nobel laureate David Baltimore (Caltech, USA)
discussed the dynamics of mRNA transcription following
inflammation and described how the temporal order of
the immune response is regulated by splicing, by measur-
ing the accumulation of unspliced mRNA. Baltimore
showed that the splice sites of late-response genes harbor
introns that contain conserved noncanonical sequences
which serve as “bottlenecks”.
Amos Tanay (Weizmann Institute of Science, Israel)
discussed new ways to study topologically associating
domains (TADs) and gene regulation within them. Tanay
introduced algorithms and new single-cell and single-
molecule assays to capture “walks” between physically
linked genomic loci. He then argued that multiway con-
tacts between enhancers can be explained by independent
pairwise interactions within the context of TADs, while si-
lenced domains can form rosette-like hubs. Ido Amit
(Weizmann Institute of Science, Israel) presented a collab-
oration with Tanay where they examined the transcriptome
of single hematopoietic progenitors and used transcrip-
tional sorting to delineate progenitor subgroups, as op-
posed to contemporary surface markers and functional
assays, and found early transcriptional priming of differen-
tiation lines, with no mixed-state progenitors. Further-
more, he demonstrated that comprehensive single-cell
analysis of bone marrow progenitors can be used to revise
the current hematopoietic tree model, defining new pro-
genitors, markers, signaling pathways, and transcriptional
lineage regulators.
Microbiome as a basis for therapeutics
The microbiome has been implicated as a target for
therapy as it affects human health, but, unlike human
genetics, it is easier to manipulate. Recurrent Clostrid-
ium difficile colitis is now commonly treated with stool
transplants, and the effect of microbial transplants on
obesity and insulin sensitivity has also been shown.
However, although probiotic and prebiotic supplementa-
tion, along with stool transplants and diet-based micro-
biome alterations, are some of the tools readily available
in the clinic, little is known about the mechanisms lead-
ing to their desired effects. Host immunity, the presence
or absence of certain metabolites, bacterial composition
and bacterial genetics are all important players in thecomplex environment of the gut, and were all addressed
at the conference.
Addressing the effect of host immunity, Richard Flavell
(Yale University, USA) observed the fraction of the gut
microbiome that is coated by immunoglobulin A (IgA),
postulating that it acts as an initiator of immune re-
sponses. In a healthy gut, IgA normally coats pathogens,
but individuals with inflammatory bowel diseases exhibit
aberrant IgA coating of microbes. Flavell introduced the
fraction of microbes coated with IgA to germ-free mice,
showing their ability to induce dysbiosis and colitis. Fi-
nally, as a prospective therapeutic avenue, Flavell showed
that immunizing against one of the aberrantly coated
species was enough to protect mice against dextran sul-
fate sodium (DSS)-induced colitis.
The importance of certain metabolites for the healthy
function of the gut microbiome was shown by Powrie.
Tying metabolite composition with host immunity, she
discussed how the short-chain fatty acid butyrate pro-
motes bone marrow-derived macrophage activity with
improved Salmonella killing. She ended with a thera-
peutic promise, showing that treating mice with butyrate
promoted host defense against Citrobacter rodentium in-
fection. Using an analysis of the compositions of micro-
biomes, Knight showed that applying a vaginal swab to
neonates born by cesarean section promoted a healthier
development of infant microbiomes. In patients with a
Clostridium difficile infection, Knight showed that stool
samples cluster outside the normal range of healthy hu-
man stool microbiota composition, but that a stool
transplant can induce a favorable change within a day.
We (presented by Eran Segal) showed a collaborative
project with Elinav in which we measured the compos-
ition and genetic function of the microbiomes of over
800 people and found them to be associated with an effect
on human glucose metabolism. We further showed that
these microbial markers are utilized in the prediction of
personal response to meals, and that the microbiome
changes in a manner that was consistent across different
individuals when the host is put on a diet designed to
lower postmeal blood glucose responses. This intricate
interplay between host diet, host health, and microbiome
compositional dynamics holds promise for the design of
new diet-based microbiome modulating therapeutics.
Concluding remarks
This meeting covered many new and exciting develop-
ments in microbiome research, immunology, and the
cross-talk between them. Due to the large number of ex-
citing and interesting talks presented in the meeting, this
report only provides a small glimpse of these topics rather
than a comprehensive view of the entire conference. Many
unpublished works were presented and we can expect
some innovative research to be published very soon.
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